Hey there, bargain hunter

While the rest of the market has been glued to tariff headlines and AI capex announcements, a quiet clearance event has been running in biotech. Retail investors fled. Institutional money has been slow to come back. And a meaningful chunk of the sector has been trading like the whole industry is broken.

It is not broken. It is on sale. And the people who need to buy — the Big Pharma CEOs staring down a $300 billion patent cliff — are already showing up with their checkbooks open.

The Scoreboard

Let’s start with the numbers that matter, because the setup here is as concrete as it gets.

• XBI (SPDR S&P Biotech ETF): Currently trading around $130. The 52-week low was $66.66. That means the ETF literally doubled off its floor — and still sits more than 25% below its 2021 all-time high of $174. There is a lot of ground left to recapture.
• Biotechs trading below cash: At mid-2025, nearly half of all publicly traded U.S. biotech companies were trading below their cash balance sheet values. Even after the M&A-driven rebound, more than 150 companies — roughly 25% of the sector — were still trading below net cash at their recent lows. That is not a valuation story. That is a panic story.
• FDA approved 46 new drugs in 2025, slightly down from 50 in 2024 and 55 in 2023, but still well above the historical average of 36 per year since 1993. More than half of 2025 approvals were first-in-class therapies. The regulatory pipeline is functioning.
• Biotech M&A in Q1 2026: Seven transactions worth a combined $29 billion closed in just the last two weeks of March alone. Jefferies analysts noted the XBI surged 64% over the prior year alongside this deal wave. The market is waking up — but slowly enough that you still have time to act.
• Big Pharma’s war chest: Pharma and large-cap biotech companies collectively hold an estimated $1 trillion in cash reserves earmarked for M&A. AbbVie alone has $33.6 billion in acquisition capacity. BMS has $21.9 billion. Novartis has $53 billion. Amgen has $18.6 billion. These are not hypothetical buyers. They are desperate ones.

Why Is This Happening?

Two forces collided and created this setup. One crushed small biotech valuations. The other is now forcing Big Pharma to go hunting.

Force No. 1: Rising rates wrecked pre-revenue biotech

Pre-revenue drug developers are essentially long-duration assets. Their value sits years in the future — trial readouts, approval decisions, eventual revenue. When the Fed raised rates aggressively starting in 2022, those future cash flows got hammered by the discount rate. The sector sold off. Hard. Between March 2021 and January 2025, the small-cap biotech index underperformed the S&P 500 by more than 110 percentage points. That is not a bad month. That is a multi-year wipeout.

Capital dried up. Venture funding in 2025 fell below historical averages. More than one-third of biotechs had under a year of cash left, according to EY’s 2025 Biotech Beyond Borders report. Companies that couldn’t raise diluted themselves or folded. The ones that survived with clean balance sheets are now the most interesting names on the board.

Force No. 2: The $300 billion patent cliff is not a warning. It is already happening.

Between now and 2030, more than $300 billion in prescription drug revenue will lose patent exclusivity. That is roughly one-sixth of the entire industry’s annual sales. Nearly 200 drugs will go generic or face biosimilar competition in this window, including approximately 70 blockbusters generating over $1 billion each in annual sales.

Here is what that looks like at the company level — and these are real numbers, not projections:

• Bristol Myers Squibb: Eliquis ($13B in 2024 BMS revenue) and Opdivo ($9B) together represent roughly 45% of total BMS revenues. Both face exclusivity losses this decade. BMS’s “growth gap” — the difference between expiring revenue and new product revenue — is estimated at $38 billion. That is the largest gap among any major pharma company.
• Merck: Keytruda, the best-selling drug in the world, is projected to peak at $32 billion in 2026 before biosimilar competition arrives in 2028. Keytruda alone represents more revenue at risk from a single product than any drug in pharmaceutical history.
• Pfizer: Eliquis (which it co-markets with BMS), Prevnar, Ibrance, and Xtandi represent over $15 billion in at-risk revenue in the 2026–2027 window.
• AbbVie: Humira revenue collapsed from $21.2 billion in 2022 to $9 billion in 2024 after biosimilar entry. AbbVie has largely managed the transition via Skyrizi and Rinvoq — but Humira was the template. What happened there is the playbook everyone else is now scrambling to execute.

By 2026, eight of the thirteen largest pharmaceutical firms — representing 55% of global market value — could see 30% or more of their revenue jeopardized, with per-company losses ranging from $6 billion to $38 billion. You cannot cut your way out of that. You have to buy your way out of it.

What the Business Actually Is

Here is how to think about a small-cap biotech with $300 million in cash, no debt, and a Phase 3 readout expected in the next 18 months.

It is not a lottery ticket. It is a call option with a known expiration date and a reasonably quantifiable probability range. The key metric is not revenue — it does not have any. The key metrics are:

• Cash runway: How many quarters does the balance sheet fund operations before a dilutive raise becomes necessary?
• Catalyst timing: When is the Phase 2 or Phase 3 data readout? Can the company survive to that date without printing shares?
• Enterprise value vs. net cash: Is the market pricing the pipeline at zero, negative, or a meaningful premium?
• Strategic fit: Is the therapeutic area on Big Pharma’s acquisition shopping list?

The names that check all four boxes — especially in oncology, rare disease, and cardiometabolic indications where 2025 M&A was most active — are the ones worth spending time on. Oncology alone accounted for 39% of total 2025 biotech transaction volume, with a clear tilt toward precision therapies.

For context on what buyers are willing to pay: J&J acquired Intra-Cellular Therapies for $14.6 billion in early 2025. Merck paid $10 billion for Verona Pharma. Sanofi paid $9.5 billion for Blueprint Medicines. Novartis paid $12 billion for Avidity. None of these targets were household names before the deal. All of them had assets that fit a specific hole in an acquirer’s pipeline. That is the playbook.

Is It Cheap?

In a word: yes — in pockets. Not everywhere, and not indiscriminately. But the sub-sector of cash-rich, pre-revenue biotechs with active late-stage programs remains historically cheap relative to what acquirers are demonstrably willing to pay.

The math works like this: If a company has $200 million in net cash, $0 in debt, and trades at a $180 million market cap, its enterprise value is negative $20 million. You are being paid to own the pipeline. That is not a rhetorical device — that is arithmetic. The downside is bounded by the liquidation value of the cash. The upside is a trial success, a regulatory approval, or a buyout premium that can be 2x to 5x the current price.

As one former Bristol Myers Squibb director said in a mid-2025 expert call: “A lot of them are trading below cash. I think there’s a lot of opportunity there for folks to find creative deal structures, and shop for their favorite asset and get it for a relatively cheap price.” That is a Big Pharma buyer describing the opportunity in plain English.

The broader deal environment confirms this. Total pharma M&A deal value reached $111 billion in 2025 — with ING projecting 15% growth in both deal value and deal count in 2026, forecasting nearly 520 deals totaling over $230 billion. If 2026 tracks that forecast, this is the most active acquisition environment in years. The companies being acquired are exactly the kind of assets sitting in the biotech basement right now.

Bull / Base / Bear

Bull Case

• M&A continues at its current 2026 pace. Jefferies already called Q1 2026 a signal that “biotech momentum can continue throughout 2026” — and the XBI’s 64% year-over-year rally entering Q1 gives dealmakers confidence to keep bidding.
• FDA approval cadence stays at or above the 46-per-year range established in 2025. First-in-class therapy approvals (more than half of 2025 approvals qualified) validate the innovation thesis.
• Interest rates moderate further, compressing the discount rate on long-duration biotech assets and re-rating cash-rich names higher even without a catalyst.
• Late-stage clinical readouts in 2026 and 2027 produce positive data across multiple pipeline companies, triggering re-rates and acquisition bids simultaneously.

Base Case

• M&A continues but gets selective. Big Pharma focuses on assets with late-stage clinical clarity and proven mechanisms. Early-stage or single-asset companies in crowded indications get passed over.
• Some names with 18-plus months of runway reach their data readouts cleanly. Positive data leads to buyout offers or partnership deals at premiums. Names with failed readouts fall back toward cash value — but the cash floor holds.
• XBI grinds higher from current levels over 12 to 24 months as the combination of M&A activity and rate moderation reduces the discount on the sector.

Bear Case

• FDA regulatory uncertainty worsens. Workforce reductions at the agency have already caused missed deadlines and less predictable feedback cycles. A sustained slowdown in approvals would pressure the entire thesis.
• Macro deterioration forces Big Pharma to pull back on M&A. Even with $1 trillion in combined acquisition capacity, a severe credit tightening or equity market crash changes the calculus for boards.
• Clinical failures cluster. In a bad stretch for binary-event stocks, multiple high-profile Phase 3 failures reset sector sentiment and push even well-capitalized names lower.
• Dilutive raises accelerate. EY found more than one-third of biotechs had under a year of cash at recent lows. Companies that cannot reach their catalyst without printing shares are not the same as companies with clean runways. Know the difference before you buy.

Action Plan

This is not a sector-wide buy-the-dip trade. The XBI is already up 64% from its lows on a year-over-year basis. The easy money from the bottom has largely been made at the index level. What remains is a stock-picker’s game — and a very good one for anyone willing to do the work.

Here is how the Cheap Investor approaches it:

• Start with the balance sheet. Enterprise value below 1.5x net cash is the entry filter. Negative enterprise value is the sweet spot. Do not touch companies burning more than $100M per year without a clear 18-month runway to catalyst.
• Map the catalyst calendar. Phase 2 or Phase 3 readouts expected within 12 to 24 months are the target window. You want enough time for the thesis to develop, but not so much time that the company dilutes you in a secondary offering before you get paid.
• Prioritize rare disease and oncology. These two categories dominated 2025 M&A activity (oncology: 39% of transaction volume; rare disease: growing share of both approvals and deal flow). Orphan drug designation adds faster regulatory path and pricing power.
• Scale in on weakness. Do not put a full position on day one. Binary-event stocks can move violently in both directions. A 1/3, 1/3, 1/3 scale-in approach over 60 to 90 days reduces timing risk on names with known catalyst windows.
• Set a hard stop tied to cash, not price. If a company announces a dilutive raise before the catalyst — especially at a discount to the current share price — that changes the thesis. Re-evaluate.

The Cheap Investor Scorecard

Run every biotech on your radar through this list before you put money to work. A name that checks 7 or more of these boxes is worth a closer look. Fewer than 5? Move on.

Bottom Line

Here is the conditional logic that drives this thesis.

If the patent cliff keeps forcing Big Pharma to buy pipeline — and $300 billion in at-risk revenue between now and 2030 makes that structural, not optional — then cash-rich small biotechs with late-stage programs in high-demand therapeutic areas will attract acquisition bids at meaningful premiums to where they trade today.

If a trial fails before a buyout arrives, then the cash floor limits your damage — provided you did the work on runway and dilution risk before you bought.

If the FDA approval cadence holds near the 46-per-year pace established in 2025 — well above the 36-per-year historical average — then the probability that a given Phase 3 asset reaches the market is not a coin flip. It is a knowable range.

The biotech basement sale will not last forever. J&J, Merck, Sanofi, Eli Lilly, and Novartis have already started clearing the shelves. AbbVie has $33.6 billion in capacity and a stated need to refill after Humira. The smart money is not waiting for the sector to get crowded again before they act.

Neither should you.

This newsletter is for informational purposes only and does not constitute investment advice. All investments involve risk. Past performance does not guarantee future results. Do your own due diligence before making any investment decision.